Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Journal (Scientific Reports, Oct 13, 2020, 10(1), 17078)
Important topics include: Potential drug interactions between GLP-1 medications and DMARDs Monitoring strategies for both conditions Whether weight loss might improve RA symptoms or treatment response Cardiovascular risk reduction strategies Safety considerations including contraindications (personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) Patients should not discontinue or modify DMARD therapy based on unproven theories about GLP-1 medications treating RA
In the SURMOUNT-1 clinical trial, participants who received Tirzepatide experienced substantial weight loss
)
More serious side effects are rare but should be discussed with a healthcare provider
US$ 20.75
US$ 29.96
US$ 23.80
